The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial is one of the largest clinical studies ever conducted in a population at moderate risk of initial events associated with cardiovascular and cerebrovascular disease (CVD). The ARRIVE trial represents an extension of Bayer's commitment to work with the scientific community to continue the exploration of Aspirin as a cornerstone of prevention of events associated with CVD. Bayer is committed to the advancement of science supporting the lifesaving and preventive benefits of Aspirin and improved outcomes in cardiovascular disease, diabetes, and other conditions.

Aspirin is one of the most extensively studied drugs in history. To date, more than 200,000 patients have been studied in more than 200 randomized clinical trials evaluating Aspirin efficacy and safety.